RNAi Nanomedicines toward Advancing Personalized Medicine: Challenges and Opportunities for Targeted Therapy in the Immune System

Our understanding of the tumorigenesis of classical Hodgkin lymphoma (cHL) and the formation of Reed–Sternberg cells (RS-cells) has evolved drastically in the last decades. More recently, a better characterization of the signaling pathways and the cellular interactions at play have paved the way for new targeted therapy in the hopes of improving outcomes. However, important gaps in knowledge remain that may hold the key for significant changes of paradigm in this lymphoma. Here, we discuss the past, present, and future of cHL, and review in detail the more recent discoveries pertaining to genetic instability, anti-apoptotic signaling pathways, the tumoral microenvironment, and host-immune system evasion in cHL.

Download Full-text

Targeting neuro–immune communication in neurodegeneration: Challenges and opportunities

Journal of Experimental Medicine ◽

10.1084/jem.20181737 ◽

2018 ◽

Vol 215 (11) ◽

pp. 2702-2704 ◽

Cited By ~ 8

Author(s):

Aleksandra Deczkowska ◽

Michal Schwartz

Keyword(s):

Immune System ◽

Cross Talk ◽

Immune Cells ◽

Therapeutic Approach ◽

Neurological Diseases ◽

Challenges And Opportunities ◽

The Cross ◽

The Brain

Immune cells patrol the brain and can support its function, but can we modulate brain–immune communication to fight neurological diseases? Here, we briefly discuss the mechanisms orchestrating the cross-talk between the brain and the immune system and describe how targeting this interaction in a well-controlled manner could be developed as a universal therapeutic approach to treat neurodegeneration.

Download Full-text

Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics—An innate immune system standpoint

Seminars in Immunology ◽

10.1016/j.smim.2017.08.015 ◽

2017 ◽

Vol 34 ◽

pp. 68-77 ◽

Cited By ~ 29

Author(s):

Yasmin Granot ◽

Dan Peer

Keyword(s):

Immune System ◽

Innate Immune System ◽

Lipid Nanoparticles ◽

Innate Immune ◽

Challenges And Opportunities ◽

Mrna Therapeutics ◽

The Right

Download Full-text

Thymoma: From Chemotherapy to Targeted Therapy

American Society of Clinical Oncology Educational Book ◽

10.14694/edbook_am.2012.32.22 ◽

2012 ◽

pp. 475-479

Author(s):

Nicolas Girard

Keyword(s):

Targeted Therapy ◽

Personalized Medicine ◽

Molecular Characterization ◽

Surgical Resection ◽

Locally Advanced ◽

Tumor Burden ◽

Advanced Tumor ◽

Druggable Targets ◽

Locally Advanced Tumor

Overview: Thymic malignancies are rare epithelial tumors that may be aggressive and difficult to treat. Thymomas are frequently eligible for upfront surgical resection. However, nearly 30% of patients present with locally advanced tumor at time of diagnosis, and chemotherapy is then used to reduce the tumor burden—possibly allowing subsequent surgery and/or radiotherapy. Metastatic and recurrent thymic malignancies may be similarly treated with chemotherapy. More recently, the molecular characterization of thymoma led to the identification of potentially druggable targets, laying the foundation to implement personalized medicine for patients.

Download Full-text

Specific Targets in Sarcoma and Developmental Therapeutics

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2010.0050 ◽

2010 ◽

Vol 8 (6) ◽

pp. 677-686 ◽

Cited By ~ 3

Author(s):

David M. Thomas ◽

Andrew J. Wagner

Keyword(s):

Targeted Therapy ◽

Growth Factor ◽

Personalized Medicine ◽

Connective Tissue ◽

Drug Development ◽

Therapeutic Agents ◽

Insulin Like Growth Factor ◽

Developmental Therapeutics ◽

Novel Therapeutic

Connective tissue tumors comprise a rich array of subtypes, many of which possess strong pathognomonic phenotypes and genotypes of therapeutic significance. This article describes recent applications of targeted and nontargeted therapeutic agents in connective tissue tumors that illustrate important themes in drug development. Targeted therapy has exploited the paradigms of oncogene and lineage addiction. In other cases, potential targets are more difficult to classify, such as the role of the insulin-like growth factor 1 pathway in Ewing's sarcoma. Understanding why these pathways seem critical in some cancers, and in some individuals but not others, is important in identifying novel therapeutic opportunities in an age of personalized medicine.

Download Full-text